FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
Roche announced today that the US Food and Drug Administration (FDA) approved Rituxan Hycela ™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection, for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukaemia (CLL).
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Food and Drug Administration (FDA) | Leukemia | Lymphoma | Pharmaceuticals | Rituxan | Skin